VistaGen Therapeutics, Inc.
VTGN
$3.16
$0.10353.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 190.48% | -107.61% | -43.07% | -34.17% | -52.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.48% | -107.61% | -43.07% | -34.17% | -52.54% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 190.48% | -107.61% | -43.07% | -34.17% | -52.54% |
| SG&A Expenses | -4.31% | 3.71% | 7.74% | 30.81% | 53.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.38% | 25.30% | 85.10% | 104.17% | 70.24% |
| Operating Income | -30.28% | -27.61% | -91.78% | -109.84% | -73.35% |
| Income Before Tax | -40.64% | -43.22% | -121.87% | -96.63% | -55.55% |
| Income Tax Expenses | -- | -100.00% | -- | -- | -- |
| Earnings from Continuing Operations | -40.64% | -43.21% | -121.87% | -96.74% | -55.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.64% | -43.21% | -121.87% | -96.74% | -55.48% |
| EBIT | -30.28% | -27.61% | -91.78% | -109.84% | -73.35% |
| EBITDA | -30.31% | -27.63% | -92.04% | -110.25% | -73.66% |
| EPS Basic | -34.79% | -38.46% | -112.26% | 35.50% | 62.72% |
| Normalized Basic EPS | -34.81% | -38.53% | -112.37% | 35.54% | 62.71% |
| EPS Diluted | -34.79% | -38.46% | -112.26% | 35.50% | 62.72% |
| Normalized Diluted EPS | -34.81% | -38.53% | -112.37% | 35.54% | 62.71% |
| Average Basic Shares Outstanding | 4.34% | 3.41% | 4.50% | 205.03% | 317.11% |
| Average Diluted Shares Outstanding | 4.34% | 3.41% | 4.50% | 205.03% | 317.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |